Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)

15 november 2026 uppdaterad av: University Health Network, Toronto

At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy

Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.

A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:

  • Get personalized resources that can help them navigate through the stages of their treatment.
  • Access vetted information about their cancer & treatment from a health library.
  • Receive surveys about their health and well-being.
  • Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
  • Connect with a physiotherapist to discuss healthy living and wellness.

Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.

At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

200

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Ontario
      • Toronto, Ontario, Kanada, M5G2M9
        • University Health Network
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Females (assigned female at birth)*
  • Diagnosed with primary invasive BC and receiving curative intent treatment
  • Must have neoadjuvant chemotherapy as their first step in treatment
  • Receiving systemic therapy at UHN
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English

Exclusion Criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/metastatic (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • Should not be enrolled in any other UHN study using an e-Health application

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Control

Standard care

Experimentell: Intervention (App)

App + standard care

The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient Activation Measure 13 (PAM-13)
Tidsram: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Impact of Events Scale - Revised (IES-R)
Tidsram: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Generalized Anxiety Disorder 7 (GAD-7)
Tidsram: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
Tidsram: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales).

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
Tidsram: 9 months post-baseline

A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information.

9 months post-baseline
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
Tidsram: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

A 42-item survey assessing quality of life specifically for breast cancer patients.

The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems.

Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
Health Education Impact Questionnaire (heiQ)
Tidsram: Baseline 9 months post-baseline

A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

Baseline 9 months post-baseline
Clinical Evaluation Questionnaire -INS (CEQ-INS)
Tidsram: 9 months post-baseline

A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

9 months post-baseline
Health Service Outcomes - Wait Times
Tidsram: Until 15 months post-baseline

The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals.

Until 15 months post-baseline
Health Service Outcomes - Ambulatory Clinical Activity
Tidsram: Until 15 months post-baseline

Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS).

Until 15 months post-baseline
Health Service Outcomes - Discharge Information
Tidsram: Until 15 months post-baseline

Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery.

Until 15 months post-baseline

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 oktober 2028

Avslutad studie (Beräknad)

1 oktober 2028

Studieregistreringsdatum

Först inskickad

28 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

15 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera